Skip to main content
SpringerLink
Log in

Fluoroquinolones in the Elderly

Safety Considerations

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Fluoroquinolones such as ciprofloxacin, levofloxacin, moxifloxacin and gatifloxacin are widely used for the treatment of bacterial infections. Fluoroquinolone-induced adverse effects have not been reported to occur with increased frequency in the elderly, but large trials comparing the tolerability in aged and young individuals are not available. Renal function declines consistently with age and recommendations for dosage changes of renally eliminated fluoroquinolones (ofloxacin, levofloxacin, gatifloxacin) are related to changes in kidney function rather than to age per se. However, during routine clinical work, creatinine clearance data are usually not available; thus it seems more practical to recommend dosage adjustment for elderly individuals in whom low creatinine clearance values can be expected.

Reactions of the gastrointestinal tract are the most often observed adverse effects during therapy with fluoroquinolones; however, compared with many other antibacterials, fluoroquinolones are less frequently associated with diarrhoea. Similarly, hypersensitivity reactions, as observed during therapy with penicillins and other β-lactam agents, occur more rarely during fluoroquinolone therapy. Adverse reactions of the CNS are of particular concern for the elderly population. Elderly patients with impairments of the CNS (e.g. epilepsy, pronounced arteriosclerosis) should be treated with fluoroquinolones only under close supervision. Probably, many signs of possible adverse reactions such as confusion, weakness, loss of appetite, tremor or depression are often mistakenly attributed to old age and remain unreported.

Fluoroquinolones can cause QT interval prolongation. Therefore, they should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalaemia or hypomagnesaemia and patients receiving class IA (e.g. quinidine, procainamide) or class III (e.g. amiodarone, sotalol) antiarrhythmic agents.

Chondrotoxicity of fluoroquinolones, as observed in immature animals, has led to restricted use in paediatric patients, but there is no indication that similar effects could occur in joint cartilage of adults. Tendinitis and tendon ruptures have occurred in rare cases as late as several months after treatment with some fluoroquinolones. Chronic renal diseases, concomitant use of corticosteroids and age over 60 years have been recognised as risk factors for fluoroquinolone-induced tendon disorders.

Overall, the widely used fluoroquinolones discussed in this review are generally well tolerated. Nevertheless, as with all drugs, their specific adverse effect profiles must be considered when they are chosen for treatment of bacterial infections. Because of physiological changes in renal function and in case of certain comorbidities, some special considerations are necessary when fluoroquinolones are used to treat elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Naber KG, Adam D. Classification of fluoroquinolones. Int J Antimicrob Agents 1998; 10: 255–7

    Article  PubMed  CAS  Google Scholar 

  2. Carbonin P, Pahor M, Bernabei R, et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991; 39: 1093–9

    PubMed  CAS  Google Scholar 

  3. Gomolin IH, Siami PF, Reuning-Scherer J, et al., and Oral Suspension Study Group. Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim: sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection. J Am Geriatr Soc 2001; 49: 1606–13

    Article  PubMed  CAS  Google Scholar 

  4. Hooper DC, Wolfson JS. Adverse effects. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents. 2nd ed. Washington (DC): American Society for Microbiology, 1993; 489–512

    Google Scholar 

  5. Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone. J Respir Dis 1999; 20 Suppl.: S70–6

    Google Scholar 

  6. Church D, Haverstock D, Andriole VT. Moxifloxacin: a review of its safety profile based on worldwide clinical trials. Today’s Ther Trends 2000; 18: 205–23

    Google Scholar 

  7. Nicolle LE. Quinolones in the aged. Drugs 1999; 58Suppl. 2: 49–51

    Article  PubMed  CAS  Google Scholar 

  8. Stahlmann R, Lode H. Fluoroquinolones. In: Root RK, Waldvogel F, Corey L, et al., editors. Clinical infectious diseases: a practical approach. New York: Oxford University Press, 1999: 305–12

    Google Scholar 

  9. Graber H, Ludwig E, Arr M, et al. Pharmacokinetics of ofloxacin in young and elderly patients [abstract]. Rev Infect Dis 1988; 10Suppl. 1: S106

    Google Scholar 

  10. Chien SC, Chow AT, Natarajan J, et al. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 1562–5

    PubMed  CAS  Google Scholar 

  11. Perry CM, Ormrod D, Hurst M, et al. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs 2002; 62(1): 169–207

    Article  PubMed  CAS  Google Scholar 

  12. Tequin™ (gatifloxacin) US Package Insert. Princeton (NJ): Bristol-Myers Squibb Company, 2001

  13. Barman Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59(1): 115–39

    Article  Google Scholar 

  14. Wiseman LR, Balfour JA. Ciprofloxacin: a review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging 1994; 4(2): 145–73

    Article  PubMed  CAS  Google Scholar 

  15. LEVAQUIN [prescribing information]. Raritan (NJ): Ortho-McNeil, 1999

  16. Springsklee M, Reiter C, Meyer JM. Safety and tolerability of moxifloxacin (MXF) [abstract 260]. Antiinfect Drugs Chemother 2000; 17(1): 90

    Google Scholar 

  17. Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999; 58Suppl. 2: 65–70

    Article  PubMed  CAS  Google Scholar 

  18. Edlund C, Beyer G, Hiemer-Bau M, et al. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 2000; 32: 81–5

    Article  PubMed  CAS  Google Scholar 

  19. Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994; 18Suppl. 4: S265–72

    Article  PubMed  Google Scholar 

  20. Ljungberg B, Nilsson-Ehle I, Edlund C, et al. Influence of ciprofloxacin on the colonic microflora in young and elderly volunteers: no impact of the altered drug absorption. Scand J Infect Dis 1990; 22: 205–8

    Article  PubMed  CAS  Google Scholar 

  21. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 352–64

    Article  PubMed  CAS  Google Scholar 

  22. Bowie WR, Willetts V, Jewesson PJ. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother 1989; 33: 1778–82

    Article  PubMed  CAS  Google Scholar 

  23. Lode H. Potential interactions of the extended-spectrum fluroquinolones with the CNS. Drugs Saf 1999; 21: 123–35

    Article  CAS  Google Scholar 

  24. Kawahara K, Kawahara M, Goto T, et al. Penetration of sparfloxacin into the human spinal fluid: a comparative study with 5 other fluoroquinolones. Chemotherapy 1991; 39: 149–57

    Google Scholar 

  25. Davey PG, Charter M, Kelly S, et al. Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. Antimicrob Agents Chemother 1994; 38: 1356–62

    Article  PubMed  CAS  Google Scholar 

  26. Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001; 35: 1194–8

    Article  PubMed  CAS  Google Scholar 

  27. Schmuck G, Schürmann A, Schlüter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 1998; 42: 1831–6

    PubMed  CAS  Google Scholar 

  28. Dembry LM, Farrington JM, Andriole VT. Fluroquinolone antibiotics: adverse effects and safety profiles. Infect Dis Clin Pract 1999; 8: 421–8

    Article  Google Scholar 

  29. Domagala JM. Structure-activity and structure-side-effect relationship for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685–706

    Article  PubMed  CAS  Google Scholar 

  30. Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999; 58Suppl. 2: 37–42

    Article  PubMed  CAS  Google Scholar 

  31. Takayama S, Hirohashi M, Kato M, et al. Toxicity of quinolone antimicrobial agents. J Toxicol Environ Health 1995; 45: 1–45

    Article  PubMed  CAS  Google Scholar 

  32. Stahlmann R, Schwabe R. Safety profile of grepafloxacin compared with other fluoroquinolones. J Antimicrob Chemother 1997; 40Suppl. A: 83–92

    Article  PubMed  CAS  Google Scholar 

  33. Anderson ME, Mazur A, Yang T, et al. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001; 296(3): 806–10

    PubMed  CAS  Google Scholar 

  34. Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59: 122–6

    PubMed  CAS  Google Scholar 

  35. Iannini PB, Kubin R, Reiter C, et al. Reassuring safety profile of moxifloxacin [correspondence]. Clin Infect Dis 2001; 32: 1112–4

    Article  PubMed  CAS  Google Scholar 

  36. Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002; 49: 593–6

    Article  PubMed  CAS  Google Scholar 

  37. Bertino JS, Owens RC, Carnes TD, et al. Gatifloxacin-associated corrected QT-interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002; 34: 861–3

    Article  PubMed  Google Scholar 

  38. Owens RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002; 22: 663–8

    Article  PubMed  Google Scholar 

  39. Avelox™ (moxifloxacin hydrochloride) Tablets, US Package Insert. West Haven (CT): Bayer Corporation, 1999

  40. Sherman O, Beizer JL. Possible ciprofloxacin-induced acute cholestatic jaundice. Ann Pharmacother 1994; 28(10): 1162–4

    PubMed  CAS  Google Scholar 

  41. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002; 127: 269–77

    Article  PubMed  CAS  Google Scholar 

  42. Grayson SM. Synthetic antibacterial and antiparasitic drugs. In: Kucers ML, TA Crowe, SM Grayson, et al., editors. The use of antibiotics. 5th ed. Oxford: Butterworth, Heinemann, 1997: 981–1060

    Google Scholar 

  43. Lomaestro BM. Fluoroquinolone-induced renal failure. Drug Saf 2000; 22: 479–85

    Article  PubMed  CAS  Google Scholar 

  44. von Keutz E, Christ W. Toxicology and safety pharmacology of quinolones. In: Kuhlmann J, Dalhoff A, Zeiler H-J, editors. Quinolone antibacterials. Handbook of experimental pharmacology, vol 127. Berlin, Heidelberg, New York: Springer-Verlag, 1998: 297–337

    Chapter  Google Scholar 

  45. Chopra N, Fine PL, Price B, et al. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation [case report]. J Urology 2000; 164: 438

    Article  CAS  Google Scholar 

  46. Förster C, Kociok K, Shakibaei M, et al. Quinolone-induced cartilage lesions are not reversible in rats. Arch Toxicol 1996; 70: 474–81

    Article  PubMed  Google Scholar 

  47. Förster C, Schwabe R, Lozo E, et al. Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics. Arch Toxicol 1997; 72: 26–32

    Article  PubMed  Google Scholar 

  48. Lozo E, Riecke K, Schwabe R, et al. Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats. Antimicrob Agents Chemother 2002; 46: 1755–9

    Article  PubMed  CAS  Google Scholar 

  49. Stahlmann R, Schwabe R, Pfister K, et al. Supplementation with magnesium and tocopherol diminishes quinoloneinduced chondrotoxicity in immature rats. Drugs 1999; 58Suppl. 2: 393–4

    Article  CAS  Google Scholar 

  50. Stahlmann R, Förster C, Shakibaei M, et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical with quinolone-induced arthropathy. Antimicrob Agents Chemother 1995; 39: 2013–8

    Article  PubMed  CAS  Google Scholar 

  51. Kahn MF, Hayem G. Tendons and fluoroquinolones: unresolved issues. Rev Rhum Engl Ed 1997; 64: 437–9

    PubMed  CAS  Google Scholar 

  52. Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie 1996; 51: 419–20

    PubMed  CAS  Google Scholar 

  53. Van der Linden PD, van de Lei J, Nab HW, et al. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999; 48: 433–7

    Article  PubMed  Google Scholar 

  54. Van der Linden PD, van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum 2001; 45: 235–9

    Article  PubMed  Google Scholar 

  55. Simonin M-A, Gegout-Pottie P, Minn A, et al. Pefloxacininduced Achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. Antimicrob Agents Chemother 2000; 44: 867–72

    Article  PubMed  CAS  Google Scholar 

  56. Shakibaei M, Pfister K, Schwabe R, et al. Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. Antimicrob Agents Chemother 2000; 44: 261–6

    Article  PubMed  CAS  Google Scholar 

  57. Shakibaei M, Stahlmann R. Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. Arch Toxicol 2001; 75: 97–102

    Article  PubMed  CAS  Google Scholar 

  58. Shakibaei M, Baumann-Wilschke I, Stahlmann R. Quinolone-induced changes in Achilles tendons from rats persist for several months [abstract]. J Antimicrob Chemother 2001; 47Suppl. S1: 49

    Google Scholar 

Download references

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Institute of Clinical Pharmacology and Toxicology, Benjamin Franklin Medical Center, Freie Universität Berlin, Garystrasse 5, Berlin, 14195, Germany

    Ralf Stahlmann

  2. Department of Chest and Infectious Diseases Heckeshorn, Hospital Zehlendorf, Berlin, Germany

    Hartmut Lode

Authors
  1. Ralf Stahlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hartmut Lode
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ralf Stahlmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stahlmann, R., Lode, H. Fluoroquinolones in the Elderly. Drugs Aging 20, 289–302 (2003). https://doi.org/10.2165/00002512-200320040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320040-00005

Keywords

Search

Navigation